Facilitation of renal kallikrein-kinin system prevents the development of hypertension by inhibition of sodium retention - PubMed (original) (raw)
Facilitation of renal kallikrein-kinin system prevents the development of hypertension by inhibition of sodium retention
M Majima et al. Immunopharmacology. 1999.
Abstract
We have previously reported that the renal kallikrein-kinin system suppressed the development of hypertension, using kininogen deficient Brown Norway Katholiek rats. Kinins were degraded in urine mainly by carboxypeptidase Y-like kininase (CPY). Blockade of renal kinin degradation may prevent the experimental hypertension through the facilitation of the renal kallikrein-kinin system. Daily administration of ebelactone B (EB), which is isolated from Actinomycetes and strongly inhibits CPY, from the first day of deoxycorticosterone acetate (DOCA)-salt treatment for 4 weeks completely blocked hypertension in Sprague-Dawley rats. This treatment reduced sodium levels in erythrocytes and cerebrospinal fluids (CSF) significantly. By contrast, an ACE inhibitor, lisinopril did not prevent hypertension. The development of hypertension in young spontaneously hypertensive rats was also blunted by EB with reductions in sodium levels in erythrocytes and in CSF. The arterial kinin levels in rats undergoing DOCA-salt treatment were 2.2 +/- 0.2 pg/ml, which were increased significantly to 4.6 +/- 0.4 pg/ml with captopril (10 mg/kg, s.c.). The increased kinin levels were less than those to show hypotension. EB did not increase the arterial kinin levels, with significant increase in urinary kinin secretion. These results suggested that facilitation of the renal kallikrein-kinin system by inhibition of kinin degradation on the luminal side of the renal tubules may effectively prevent hypertension.
Similar articles
- Inhibition of kinin degradation on the luminal side of renal tubules reduces high blood pressure in deoxycorticosterone acetate salt-treated rats.
Nakajima S, Ito H, Hayashi I, Kuribayashi Y, Okumura T, Yajima Y, Katori M, Majima M. Nakajima S, et al. Clin Exp Pharmacol Physiol. 2000 Jan-Feb;27(1-2):80-7. doi: 10.1046/j.1440-1681.2000.03209.x. Clin Exp Pharmacol Physiol. 2000. PMID: 10696533 - Role of the renal kallikrein-kinin system in the development of salt-sensitive hypertension.
Katori M, Majima M, Hayashi I, Fujita T, Yamanaka M. Katori M, et al. Biol Chem. 2001 Jan;382(1):61-4. doi: 10.1515/BC.2001.010. Biol Chem. 2001. PMID: 11258674 Review. - In vivo transfer of antisense oligonucleotide against urinary kininase blunts deoxycorticosterone acetate-salt hypertension in rats.
Hayashi I, Majima M, Fujita T, Okumura T, Kumagai Y, Tomita N, Morishita R, Higaki J, Ogiwara T. Hayashi I, et al. Br J Pharmacol. 2000 Oct;131(4):820-6. doi: 10.1038/sj.bjp.0703634. Br J Pharmacol. 2000. PMID: 11030733 Free PMC article. - Crucial suppressive role of renal kallikrein-kinin system in development of salt-sensitive hypertension.
Katori M, Majima M, Hayashi I. Katori M, et al. Biol Res. 1998;31(3):143-9. Biol Res. 1998. PMID: 9830501 Review. - Role of the renal kallikrein-kinin system in the development of hypertension.
Katori M, Majima M. Katori M, et al. Immunopharmacology. 1997 Jun;36(2-3):237-42. doi: 10.1016/s0162-3109(97)00029-5. Immunopharmacology. 1997. PMID: 9228552
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous